ASGCT
From decoy DNA sequences to plasmapheresis, researchers are testing strategies to get around anti-AAV antibodies that hinder gene therapy response.
Precision Medicine Supporters Worry About NIH Indirect Rate Cut's Impact on Advances, Workforce
Premium
Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.
FDA Platform Designation Program Could Ease Path to Market for Gene-Editing Therapies
In a draft guidance, the agency outlined how the well-understood and reproducible components of genetic medicines could qualify as platform technologies.
Cell and Gene Therapy Pricing Model Remains Sticking Point Despite CMS Efforts to Defray Costs
Premium
Despite some CMS policies designed to improve patient access to cell and gene therapies, the reliance on a value-based pricing model drew sharp criticism in an ASGCT session.
Regeneron Gene Therapy Restores Hearing in Infant With Genetic Form of Deafness, Data at ASGCT Show
Premium
The 10-month-old patient was treated with DB-OTO, a gene therapy developed by Decibel Therapeutics, which Regeneron acquired last year.